𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

✍ Scribed by S. Negrier; E. Jäger; C. Porta; D. McDermott; M. Moore; J. Bellmunt; S. Anderson; F. Cihon; J. Lewis; B. Escudier; R. Bukowski

Book ID
107576930
Publisher
Springer US
Year
2009
Tongue
English
Weight
316 KB
Volume
27
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy results of the advan
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
✍ Walter M. Stadler; Robert A. Figlin; David F. McDermott; Janice P. Dutcher; Jenn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract ## BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. ## METHODS: In this nonrandomized, open‐label expanded access program, 2504 patients from the United St

Upfront, randomized, phase 2 trial of so
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis
✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Thirteen-year, long-term efficacy of int
Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
✍ Jens Atzpodien; Reinhard Hoffmann; Marcus Franzke; Christian Stief; Thomas Wande 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Background: The goal of the current report was to demonstrate the long-term efficacy of outpatient subcutaneous (sc) interferon alpha (ifn-alpha) and sc interleukin 2 (il-2)-based combination regimens in patients with metastatic renal cell carcinoma. ## Methods: In three consecutive clinical t